`U.S. Patent No. 9,549,938
`
`
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`__________________
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`__________________
`
`MYLAN PHARMACEUTICALS INC.,
`Petitioner,
`
`v.
`
`ANACOR PHAMACEUTICALS, INC.,
`Patent Owner
`__________________
`
`Case No. IPR2018-01358
`U.S. Patent No. 9,549,938
`__________________
`
`PATENT OWNER’S OPPOSITION TO
`PETITIONER’S MOTION FOR JOINDER
`
`
`
`
`
`Petitioner Mylan Pharmaceuticals Inc. (“Mylan”) has filed a motion seeking
`
`Case No. IPR2018-01358
`U.S. Patent No. 9,549,938
`
`
`joinder with IPR2018-00168 filed by FlatWing Pharmaceuticals, Inc. (“Flatwing”).
`
`The Board instituted IPR2018-00168 on June 8, 2018, and issued a scheduling
`
`order setting oral argument for March 1, 2019.
`
`Patent Owner Anacor Pharmaceuticals, Inc. (“Anacor”) opposes Mylan’s
`
`motion to the extent that Mylan is not confined to a true “silent understudy” role.
`
`Famy Care Ltd. v. Allergan, Inc., IPR2017-00567, Paper No. 12 at 9 (P.T.A.B.
`
`July 10, 2017). Although Mylan’s motion expresses a purported willingness to
`
`limit the extent of its participation in the joined proceedings, Mylan has proposed
`
`no specific limits on its ability to engage in discovery, briefing, and trial.
`
`Three particular issues with Mylan’s motion are illustrative. First, Mylan
`
`raises the possibility that it will make separate filings after seeking authorization
`
`from the Board to address any disagreements with FlatWing. Mot. at 6. This, of
`
`course, would require the Board to resolve a potential dispute among the parties
`
`each time Mylan seeks to press its own case. While Mylan asserts that any
`
`separate filing will be “short,” it has not committed to any specific type or volume
`
`limitation. And although Mylan states that its current petition is a “practical” or
`
`“substantive” copy of Flatwing’s, Mot. at 1–2, Mylan has not restricted itself from
`
`raising new arguments and issues. Second, Mylan states that it will “coordinate
`
`with FlatWing” to “manage questioning at depositions.” Mot. 7. This vague
`
`
`
`pronouncement suggests that Mylan will seek an active role in discovery. Third,
`
`Case No. IPR2018-01358
`U.S. Patent No. 9,549,938
`
`
`by not discussing its desired role at oral argument, Mylan presumably will seek
`
`some level of participation at that time. See Famy Care, Paper No. 12 at 9
`
`(denying joinder where subsequent petitioner insisted on participating in oral
`
`argument). Thus, it is not at all clear that Mylan has actually committed to an
`
`understudy role, much less a “silent” one.
`
`Mylan suggests that in granting joinder, the Board may adopt “similar”
`
`limits to those it has imposed in the past. Mot. at 6 (citing cases). But as discussed
`
`above, Mylan has agreed to few, if any, specific limits, and the additional
`
`complexity Mylan seeks to add to FlatWing’s IPR will prejudice Anacor.
`
`Nevertheless, consistent with limitations that the Board has previously imposed on
`
`“understudies,” Anacor will not oppose joinder if: (a) the joined proceedings are
`
`based exclusively on the petition and evidence submitted by FlatWing; (b) all
`
`filings by Mylan in the joined proceeding are consolidated with FlatWing’s and the
`
`page limits and word counts set forth in 37 C.F.R. § 42.24 apply to all such
`
`consolidated briefing; (c) Mylan is bound by any agreements between Anacor and
`
`FlatWing concerning discovery and/or depositions; (d) Mylan at deposition shall
`
`not receive any direct, cross-examination, or redirect time beyond that permitted
`
`for FlatWing alone under either 37 C.F.R. § 42.53 or any agreement between
`
`Anacor and FlatWing; and (e) Mylan will not participate in oral argument. See
`
`
`
`Mylan Pharm. Inc. v. Novartis AG, IPR2015-00268, Paper No. 17 at 5 (P.T.A.B.
`
`Case No. IPR2018-01358
`U.S. Patent No. 9,549,938
`
`
`Apr. 10, 2015); see also Navico, Inc. v. Garmin Switz. GmbH, IPR2017-02051,
`
`Paper No. 8 at 7–8 (P.T.A.B. Jan. 23, 2018); Famy Care, Paper No. 12 at 9.
`
`
`Date: August 6, 2018
`
`
`
`
`
`
`
` Respectfully submitted,
`
`/Aaron P. Maurer/
`Aaron P. Maurer
`Reg. No. 44,911
`Lead Counsel for Patent Owner
`
`Williams & Connolly LLP
`725 Twelfth Street, N.W.
`Washington, DC 20005
`T: (202) 434-5282
`F: (202) 434-5029
`amaurer@wc.com
`
`
`
`
`Case No. IPR2018-01358
`U.S. Patent No. 9,549,938
`
`
`CERTIFICATE OF SERVICE (37 C.F.R. § 42.6(e))
`
`The undersigned hereby certifies that a true and correct copy of the
`
`
`
`foregoing document was served on August 6, 2018, by delivering a copy via
`
`electronic mail on the following attorneys of record for the Petitioner:
`
`Steven W. Parmelee
`Michael T. Rosato
`Jad A. Mills
`Wilson Sonsini Goodrich & Rosati
`701 Fifth Avenue, Suite 5100
`Seattle, WA 98104-7036
`sparmelee@wsgr.com
`mrosato@wsgr.com
`jmills@wsgr.com
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`/Anthony H. Sheh/
`Anthony H. Sheh
`Reg. No. 70,576
`
`
`
`
`